Lentiviral vectors in cancer immunotherapy. Immunotherapy 2015;7(3):271-84
Date
03/26/2015Pubmed ID
25804479DOI
10.2217/imt.14.108Scopus ID
2-s2.0-84925805603 (requires institutional sign-in at Scopus site) 26 CitationsAbstract
Basic science advances in cancer immunotherapy have resulted in various treatments that have recently shown success in the clinic. Many of these therapies require the insertion of genes into cells to directly kill them or to redirect the host's cells to induce potent immune responses. Other analogous therapies work by modifying effector cells for improved targeting and enhanced killing of tumor cells. Initial studies done using γ-retroviruses were promising, but safety concerns centered on the potential for insertional mutagenesis have highlighted the desire to develop other options for gene delivery. Lentiviral vectors (LVs) have been identified as potentially more effective and safer alternative delivery vehicles. LVs are now in use in clinical trials for many different types of inherited and acquired disorders, including cancer. This review will discuss current knowledge of LVs and the applications of this viral vector-based delivery vehicle to cancer immunotherapy.
Author List
Oldham RA, Berinstein EM, Medin JAAuthor
Jeffrey A. Medin PhD Professor in the Pediatrics department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AnimalsCancer Vaccines
Drug Delivery Systems
Genetic Engineering
Genetic Vectors
Humans
Immunotherapy
Lentivirus
Neoplasms
